Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.48 |
| ▸ | ITGAV | P06756 | 4/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 9/20 | 0.47 |
| ▸ | MC5R | P33032 | 9/20 | 0.47 |
| ▸ | MC3R | P41968 | 9/20 | 0.47 |
| ▸ | MC1R | Q01726 | 9/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19605464 | 0.93 | MC4R (0.55) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL25474210 | 0.93 | MC4R (0.55) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL14883291 | 0.93 | MC4R (0.49) | PIN1ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL10000329 | 0.93 | CACNA1B (0.49) | PIN1ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL15853554 | 0.92 | MC4R (0.46) | PIN1ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL29666716 | 0.92 | PIN1 (0.46) | PIN1ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL22872754 | 0.90 | ITGB3 (0.49) | PIN1ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL12146076 | 0.90 | ITGB3 (0.50) | PIN1ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL29569086 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL27423920 | 0.90 | MC4R (0.48) | ITGB3ITGAVITGB1ITGA5MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | ENTRADA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | PRCP, TAP1, DNPEP | PIN1 1166/4885ITGB3 4650/4885ITGAV 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.